Clinical Trials Logo

Atrophy, Geographic clinical trials

View clinical trials related to Atrophy, Geographic.

Filter by:
  • None
  • Page 1

NCT ID: NCT03845582 Active, not recruiting - Clinical trials for Age Related Macular Degeneration

Phase 3 Study of ALK-001 in Geographic Atrophy

SAGA
Start date: May 7, 2019
Phase: Phase 3
Study type: Interventional

This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.

NCT ID: NCT02033668 Completed - Atrophy, Geographic Clinical Trials

Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers

Start date: January 22, 2014
Phase: Phase 1
Study type: Interventional

This study is intended to enable a possible transition to intramuscular (IM) or subcutaneous (SQ) administration for subsequent studies with GSK933776 by characterizing the safety, tolerability, PK and pharmacodynamic profiles, and immunogenicity of GSK933776 following IM and SQ administration in healthy volunteers. Such alternate routes of administration may provide more options in the selection of an efficacious dose for subsequent development in patients with geographic atrophy. There will be four treatment arms in the study and participants will be assigned to 1 of 4 possible treatment arms in a 1:1:1:1 ratio. The planned number of evaluable participants for this study is 24 with 6 participants completing all critical assessments in each of the four treatment arms. The total duration of participation from screening to follow-up for Treatment Arms A, B and D (single dose of GSK933776), will be approximately 113 days and total duration for Treatment Arm C (repeat dose of GSK933776) will be approximately 134 days.

NCT ID: NCT01342926 Completed - Atrophy, Geographic Clinical Trials

Clinical Study to Investigate Safety and Efficacy of GSK933776 in Adult Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Start date: June 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of GSK933776 in the treatment of geographic atrophy secondary to age-related macular degeneration.